We are pleased to share that EFM has completed a project fully dedicated to preparing and submitting our application to the EIC Accelerator – one of the most important European funding programmes for breakthrough innovations. What was done under the project? The project MUDISOCARD focused on strengthening our chances in this highly competitive programme. With professional support we: Carried out in-depth analyses, like Freedom to Operate (FTO), Prepared all formal and strategic application materials, Produced a professional video presentation required for the application, Structured our application in line with the best practices and expectations of the evaluators. Who benefits? Directly: EFM, by improving our ability to secure funding and international recognition, Indirectly: doctors, patients, insurers, and healthcare systems, who will ultimately benefit if our project Mudisocard receives EIC support and can scale across Europe. Goals of the project The main goal was to apply to the EIC Accelerator with the highest possible quality of application documents. In doing so, we aimed to: Submit a complete and competitive proposal, Achieve the Seal of Excellence, Secure at least 50% of evaluation points, Follow at least two of the “6R rules”: Reuse and Reduce. Expected results As a result of this initiative, EFM has been able to prepare and submit a professional EIC Accelerator application, supported by high-quality documentation and expert analyses. The project is expected to strengthen our position in Europe, increase our visibility among potential partners and investors, and create the basis for further development. By targeting outcomes such as obtaining the Seal of Excellence, reaching at least half of the available evaluation points, and adhering to sustainable practices like Reuse and Reduce, the project has not only improved our application quality but also enhanced our long-term competitiveness.M Project value and EU support Project value: 107,000.00 PLN EU contribution: 100% This project was made possible thanks to the support of the European Union, which enabled us to apply to the EIC Accelerator at a professional level and continue our mission to bring innovative healthcare solutions to market.

EFM announces it has received Intention to Grant a European patent from the European Patent Office covering the Mudisocard system. This is the second major milestone this month. Few days ago EFM has received the Management System as per “PN-EN ISO 13485:2016-04 Medical devices - Quality management systems - Requirements for regulatory purposes” awarded by TUV NORD Polska. Mudisocard covers full dynamics of the heart including: the heart contraction excitation (ECG), parameters on how the contraction develops (auscultation) and what is contraction effect, i.e. how the chest fluids move (bioimpedance). In between the heartbeats, the device detects air movements in the human chest. The airflow generates changes in bioimpedance and creates sounds detected by auscultation. Mudisocard has the unique potential to become, in its further development, a foundation for innovative future diagnostic methods.

W ubiegłym tygodniu mieliśmy ogromną przyjemność uczestniczyć w Dniu Inwestora podczas Deep Tech CEE Summit & Challenge. W ciągu dwóch dni odbyliśmy szereg wnikliwych spotkań i angażujących dyskusji. Dziękujemy za każde spotkanie! To był pierwszy raz, kiedy mogliśmy publicznie zademonstrować funkcjonalny prototyp naszego urządzenia Mudisocard. Do zobaczenia na kolejnym wydarzeniu!

We are excited to announce that EFM has received the Management System as per “PN-EN ISO 13485:2016-04 Medical devices - Quality management systems - Requirements for regulatory purposes” awarded by TUV NORD Polska. This is another significant step towards the commercialisation of our Mudisocard system. Mudisocard covers full dynamics of the heart including: the heart contraction excitation (ECG), parameters on how the contraction develops (auscultation) and what is contraction effect, i.e. how the chest fluids move (bioimpedance). In between the heartbeats, the device detects air movements in the human chest. The airflow generates changes in bioimpedance and creates sounds detected by auscultation. Mudisocard has the unique potential to become, in its further development, a foundation for innovative future diagnostic methods.

On February 14, Miłosz Jamroży Jamrozy, CEO of EFM, had the extreme pleasure of pitching our company in front of an audience of mentors, business leaders and the startup community 💎 It is a great honor for EFM R&D to be in the Top 10 startups from nearly 200 innovative companies from across the world 👍 Congratulations and greetings to all companies: URVIS.BIKE, ARPLATFORM, Seafoo P.S.A., Lita Health, ARIBO, iYoni App, Atmesys, elerGreen Industry, WeavAir, CloEE, Magnomer.

We are happy to share the latest article from the Puls Biznesu, featuring an interview with Miłosz Jamroży, CEO of EFM. Key highlights from the article: ☑ EFM is developing a device that can measure the heart in three dimensions, not just in a plane as in a classic ECG. ☑EFM already has a prototype of the diagnostic device, has submitted patent applications in Poland and key foreign markets, and has signed an agreement with a CRO, as well as with the National Institute of Cardiology in Anin, where it is to pilot test its system. ☑ EFM plan to raise capital to realize upcoming milestones. We are considering various financing options, including venture capital. In the longer term, EFM also does not rule out an IPO Check out the full interview: https://www.pb.pl/efm-szuka-kapitalu-na-patrzenie-w-serce-1206342

A moment instead of many visits to doctors. EFM R&D device will accurately diagnose the heart. Please read the interesting article in Rzeczpospolita newspaper about our company. In just over a year of operation, we have successfully developed a functional Mudisocard prototype and submitted patent applications in the EU, US, UAE, Saudi Arabia and South Korea. - In addition, we have implemented a quality management system that has passed a Tuv Nord audit. We have established cooperation with a global CRO company and the Institute of Cardiology in Anin, we have developed regulatory strategies in the EU and the US, and we have submitted an application in the PARP grant competition- said Miłosz Jamroży, CEO of EFM. - In the next step, we want to refine the prototype and start larger-scale production. We will also develop algorithms to analyse the test results - said Miłosz Jamroży. Read more: https://cyfrowa.rp.pl/biznes-ludzie-startupy/art39510631-chwila-zamiast-wielu-wizyt-u-lekarzy-polskie-urzadzenie-dokladnie-zbada-serce